Show simple item record

Authordc.contributor.authorSaavedra, Kathleen 
Authordc.contributor.authorValbuena, José 
Authordc.contributor.authorOlivares, Wilda 
Authordc.contributor.authorMarchant, María José 
Authordc.contributor.authorRodríguez, Andrés 
Authordc.contributor.authorTorres Estay, Verónica 
Authordc.contributor.authorCarrasco Avino, Gonzalo 
Authordc.contributor.authorGuzmán, Leda 
Authordc.contributor.authorAguayo González, Francisco 
Authordc.contributor.authorRoa, Juan Carlos 
Authordc.contributor.authorCorvalán, Alejandro H. 
Admission datedc.date.accessioned2015-09-28T13:33:10Z
Available datedc.date.available2015-09-28T13:33:10Z
Publication datedc.date.issued2015
Cita de ítemdc.identifier.citationPLoS ONE 10(5): e0125834 May 8, 2015en_US
Identifierdc.identifier.otherDOI: 10.1371/journal.pone.0125834
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/133894
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractReprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at G2/M, has been proposed as a putative tumor suppressor gene (TSG) and as a potential biomarker for non-invasive detection of gastric cancer (GC). The aim of this study was to evaluate the epigenetic silencing of RPRM gene by promoter methylation and its tumor suppressor function in GC cell lines. Furthermore, clinical significance of RPRM protein product and its association with p53/p73 tumor suppressor protein family was explored. Epigenetic silencing of RPRM gene by promoter methylation was evaluated in four GC cell lines. Protein expression of RPRM was evaluated in 20 tumor and non-tumor matched cases. The clinical significance of RPRM association with p53/p73 tumor suppressor protein family was assessed in 114 GC cases. Tumor suppressor function was examined through functional assays. RPRM gene expression was negatively correlated with promoter methylation (Spearman rank r = -1; p = 0.042). RPRM overexpression inhibited colony formation and anchorage-independent growth. In clinical samples, RPRM gene protein expression was detected in 75% (15/20) of non-tumor adjacent mucosa, but only in 25% (5/20) of gastric tumor tissues (p = 0.001). Clinicopathological correlations of loss of RPRM expression were significantly associated with invasive stage of GC (stage I to II-IV, p = 0.02) and a positive association between RPRM and p73 gene protein product expression was found (p<0.0001 and kappa value = 0.363). In conclusion, epigenetic silencing of RPRM gene by promoter methylation is associated with loss of RPRM expression. Functional assays suggest that RPRM behaves as a TSG. Loss of expression of RPRM gene protein product is associated with the invasive stage of GC. Positive association between RPRM and p73 expression suggest that other members of the p53 gene family may participate in the regulation of RPRM expression.en_US
Patrocinadordc.description.sponsorshipCONICYT-FONDECYT from the Government of Chile 1111014 CONICYT-FONDAP from the Government of Chile 15130011en_US
Lenguagedc.language.isoenen_US
Publisherdc.publisherPublic Library Scienceen_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectSuppressoren_US
Keywordsdc.subjectHypermethylationen_US
Keywordsdc.subjectMethylationen_US
Keywordsdc.subjectRisken_US
Títulodc.titleLoss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Canceren_US
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile